Stocktoria
LivaNova PLC LIVN
LivaNova PLC (LIVN) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $1.4B at a -17.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.28 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-07-01 | Freedom Capital Markets | Hold (init) |
| 2026-06-22 | Keybanc | Overweight (main) |
| 2026-05-07 | Barclays | Equal-Weight (main) |
| 2026-05-07 | Mizuho | Outperform (main) |
| 2026-05-07 | Baird | Outperform (main) |
| 2026-02-27 | Barclays | Equal-Weight (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.113 |
| Retained earnings / assets | -0.44 |
| EBIT / assets | 0.077 |
| Equity / liabilities | 0.853 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LIVN | LivaNova PLC | 4/9 | 0.72 | — | +10.7% |
| CNMD | CONMED Corp | 5/9 | 2.97 | 23 | +5.2% |
| MASI | MASIMO CORP | 7/9 | 6.71 | — | +9.4% |
| ITGR | Integer Holdings Corp | 6/9 | 3.52 | 31 | +8% |
| TMDX | TransMedics Group, Inc. | 6/9 | 4.04 | 12.4 | +37.1% |
| AXGN | Axogen, Inc. | 5/9 | -0.43 | — | +20.2% |
| OM | Outset Medical, Inc. | 6/9 | -9.87 | — | +5.1% |
About LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression. This segment also includes the development and clinical testing of LivaNova's aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, and other healthcare professionals, hospitals, and other medical institutions and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
FAQ
Is LIVN financially healthy?
LivaNova PLC's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does LIVN pay a dividend?
No, LivaNova PLC does not currently pay a dividend.
How profitable is LIVN?
In FY2025, LivaNova PLC had a net margin of -17.5% and a return on equity of -20.2%.
What is the analyst price target for LIVN?
The average Wall-Street price target for LivaNova PLC is $81.45, about 0.8% above the recent price, from 11 analysts (consensus: buy).
Is LIVN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on LivaNova PLC: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.